PLAAT3 and osteosarcoma: Thus, the above results demonstrated that PLA2G16 expression may contribute to chemotherapy resistance, and it can be a potential target for the combination therapy using lipase inhibitors together with classic anticancer drugs in osteosarcoma patients.